Thank you, Andrei.
our described, impressive of CLOVER prepping study WaM be pivotal Andre with We time. data the the review submission. engaged from for As improves quite continues WaM CLOVER near-term clinical and to in the remain NDA the and cleaning study actively data
aware, attention relentless to process submission a you time-consuming requires project. is As and detail NDA are the
identifying clinical submission. the the report can database produced required completion study study the points errors. validated sections of NDA sets a of the and for collected your the must for the over This Once and which is verified. any is correcting this entry final For patient cleaning, study background, process called is be data information complete, the thousands includes clinical of is the This and the data process data of the locked data course be NDA. also and
in process of these by several activities this are We parallel. performing expediting
to be X X the traditional of a shorten of finalized, line. data to results the of line the this to submission finalized. time us data subset report both entirety submission allows required a the months the sections rather around clinical waiting to to NDA than complete final clean study is the X of to as example, we to months for This and study to in For time approximately use and X submit that data
final we with one submission need interactions of meets for In addition our closely to FDA study to these the prior with of determination work And ensure submission continue planned include study. XXXX. potential plan the the design the should to the chain. to pre-NDA FDA all requirements activities, the on confirmatory and the confirmatory agreement the FDA the a QX meeting supply for now submission to require Shifting remaining
logistics and radiopharmaceuticals some a [ supply supply manufacture of and for have rate pharmaceuticals. X organizations. are for to components essentially ] Our the chain challenge been main There of
second, produce targeting ligand, the and or the combined due and third, sites the product. to to radioactive facilities supply these of Both infrastructure First, isotope; and specialized carrier isotopes. necessary isotopes production of the the finished are are of strategy relationships drug development contract Cellectar, it's early sources process. to these adopted limited, selected our whether suppliers directly iodine-XXX with the in a we establish to and actinium-XXX there isotope globally.
At have
As for iodine-XXX. which discussed XXX, previously, I utilizes iopofosine
We have validated to continue and suppliers separate contracted X with additional suppliers. and assess
approach provide sufficient employed development steps, supply beta the throughout with the into OG-emitting. for of to program, current they weekly a isotope commercialization. provide actinium redundancy of which a drug XXX iopofosine can are actinium, is future and either week.
The partners actinium variety our uninterrupted same both we multiple allow or radio or suppliers This for model Our are is times be will partnering existing alpha, whether of employed I production being in and process supply
least allow with capacity needed. our forecasted will of greater Currently, from ] and key to is second our batch would validated the sourcing X-year naval the other is platform. iopofosine than ligand supply we of as single to secured The of increase supply enough the strategy, PLE, for support which targeting volumes XXX contractors. one and ligand the program sourcing multiple at support maximum a at to and I targeting basis sales a Similar component ligand isotope or produces targeting [
ready-to-use are in production XXX America to sites we also doses to that as multi-sourcing with finished approximately capability week product. can the iopofosine doses. X We patient capacity current I XXX nearly have the at X,XXX currently scale weekly Finally, supply fully North per
future outsourcing In addition finished the with product manufacturing significantly provides we reduced internal associated capability. expenditure supplying our costs maintenance additional an requirements, to have model our capital and benefits.
One,
for demonstrated the multiple XXX the transfer manufacturing complete I into transition have needed. organization's facility as technology to sites, to ability we and in iopofosine allows process Second, efficient timely the another rapid which
addressing to radiopharmaceuticals, taken to unique addition issues have potential logistics. with addressing In similar potential a we production approach to constraints
life care developed and shelf provides greater treatment unique novel provides a This that I iopofosine XXX We total a treatment produced. to in lower and drug formulation in for schedule I have system. patients cost waste, once XX-day reduction the iopofosine advantage by resulting a XXX flexibility likely of health a physicians with
approach delivery production, with and and our partnered to maximum treatment XX global of sourcing hours days to patient. days ensure minimum a like Additionally, a logistics of organizations within dose we manufacturing with XX of a XX XX have to materials, of sites ensuring to shipping multiple the
to today described, we supply robust built chain the future. requirements As the that I us into and XXX and meet iopofosine for allows a product finished redundant have
being for programs research commercial our as Shane? the replicated like actinium and outsourced therapeutic update. Additionally, will this now needed.
I is turn the commercialization clinical for to our Shane radio other to model call modular supply ensure program
